BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

摩根士丹利：将BioNTech的目标价从145美元下调至139美元，维持“增持”评级。(格隆汇) ...

BMO Capital：将BioNTech的目标价从130美元上调至143美元，维持“跑赢大盘”评级。(格隆汇) ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Despite these positive results, BioNTech’s stock fell by 2.88% in pre-market trading to 105.65 USD. According to InvestingPro analysis, the company maintains a "GOOD" financial health score ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Wall Street expects BioNTech SE BNTX to report quarterly earnings at 58 cents per share on revenue of $1.15 billion before ...

German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...

The company also reported revenues of 1.19 billion USD, exceeding the anticipated 1.12 billion USD. Despite these positive results, BioNTech’s stock fell by 2.88% in pre-market trading to 105.65 USD.